All Home Raises ₹200 Cr: PharmEasy Founders' New Bet

The founders who built PharmEasy have a new problem they want to solve — and it has nothing to do with medicine. All Home, their Mumbai-based interior design and architecture startup, has just closed a ₹200 crore funding round, doubling its valuation to ₹2,000 crore in under a year. The question worth asking is: what exactly are they building, and does the opportunity justify the price?

Key takeaways at a glance:

• All Home operates in interior design and architecture — specifically the building materials supply chain.

• It partners with brands by investing in them and providing technology, manufacturing, and distribution support.

• The business closed FY2026 with ₹180 Cr in revenue and is tracking ₹400 Cr annualised.

• Valuation has doubled from seed round to this round in roughly 12 months.

• The founders identified a genuine gap: a deeply unorganised building materials market with poor designer and consumer experience.

All Home is not a typical interior design marketplace. It operates across four product categories — surfaces, hardware and bath fittings, facades and windows, and lighting — and plans to add more categories over the next few quarters.

What makes the model different is how it works with brands. Rather than simply listing products, All Home partners with brands by investing in them and providing capabilities they typically lack: proprietary technology, internet-led manufacturing, distribution infrastructure, and market insights. Think of it less as a platform and more as a full-stack operating partner for building materials brands.

The capital from this round will go toward strengthening the technology stack, expanding experience centres, and building manufacturing facilities. This is a capital-intensive build — not a pure software play.

The building materials segment in India is deeply fragmented. Designers and architects typically have to coordinate with multiple vendors for a single project, deal with long turnaround times, inconsistent product quality, poor design cohesion across categories, and inadequate after-sales support.

All Home is positioning itself as the entity that fixes all of this in one place. By owning or partnering deeply with brands across categories, it aims to give designers a single point of accountability — from product selection to final installation. This is a real problem, and anyone who has renovated a home in India knows exactly how painful the current process is.

India's booming real estate sector, rising premiumisation of residential and commercial spaces, and growing consumer demand for transparency in design outcomes are all pushing demand for a more organised, reliable solution in this space.

The ₹200 crore round is a mix of equity and debt. Bessemer Venture Partners, an existing backer, led the equity portion — a signal of continued conviction from an investor that already knows the business well. Stride Ventures provided the debt component.

The round values All Home at ₹2,000 crore — exactly double the valuation at its seed round in June 2025, when it raised $20 million (approximately ₹180 crore at prevailing exchange rates). That is a very fast re-rating for a company still in its early years of operation.

All Home closed FY2026 — its first full year of operations — with revenue of approximately ₹180 crore. It is currently tracking an annualised revenue run rate of ₹400 crore. That kind of trajectory in year one of operations is what attracted Bessemer back into the round.

However, investors should note that revenue run rate and actual booked revenue are different things. The ₹400 crore figure is a forward projection based on current momentum, not an audited number. Actual profitability, margins, and unit economics have not been publicly disclosed.

For any investor watching this space, the key number to track over the next 12–18 months is whether actual revenue lands anywhere near that ₹400 crore run rate.

The founding team brings both recognition and scrutiny. Dharmil Sheth, Dhaval Shah, Hardik Dedhia, and Siddharth Shah built PharmEasy into one of India's most well-known health-tech platforms before a turbulent period that included a failed IPO attempt and valuation markdowns.

The All Home bet is that the same founders who understood supply-chain complexity in pharma can now apply those instincts to building materials. There are genuine parallels: fragmented suppliers, opaque pricing, multi-vendor coordination, and a consumer base hungry for a better experience.

Whether their pharma-era stumbles make institutional investors cautious or whether this is seen as a fresh chapter will likely influence how the next funding round is priced.

All Home is an early-stage bet on organising one of India's most chaotic consumer categories. The founding team is credible, the problem is real, the macro tailwind is strong, and Bessemer's continued backing adds weight to the story. But at ₹2,000 crore valuation on ₹180 crore of first-year revenue, the market is pricing in significant future execution. Investors interested in this space should watch actual revenue delivery against the ₹400 crore run rate claim before drawing conclusions on whether the valuation is justified.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All financial figures are sourced from publicly available news reports and have not been independently verified. Investors should conduct their own due diligence and consult a SEBI-registered investment advisor before making any investment decision.